News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute myelogenous leukemia (AML)] News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO)     9/20/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug     9/8/2016
FDA Berates Celator Pharma (CPXX) for Pushing Unapproved Leukemia Drug to Doctors     9/8/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA     8/1/2016
Ultragenyx (RARE) Rising on Phase III Acute Myeloid Leukemia Data     7/15/2016
Celator Pharma (CPXX) Jumps on Breakthrough Therapy Win for Lead Cancer Drug     5/19/2016
3 Biotechs Getting Another Shot After Failed Trials     4/7/2016
Celator Pharma (CPXX) Stock Jumps 400% Premarket as AML Drug Wows in Phase III Study     3/16/2016
Akinion Halts Further Development of AKN-028 Due to Safety Concerns     3/4/2016
Forty Seven Launches with Half of $75 Million Series A Backed by Google (GOOG) and 100+ Patents     2/26/2016
Novartis AG (NVS)'s Leukemia Drug Gets Breakthrough Designation, Same Week as AstraZeneca PLC (AZN) and Roche (RHHBY) Drugs     2/22/2016
AbbVie (ABBV)'s Venetoclax Wins 3rd Breakthrough Tag from the FDA     1/28/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014

News from Around the Web
Less Is More With Acute Myeloid Leukemia Drug, Erasmus University Medical Center Study     3/17/2011
Mutations in Single Gene Predict Poor Outcomes in Adult Leukemia; Discovery May Guide Treatment for Acute Myeloid Leukemia, Washington University Study     11/11/2010
Protein That Predicts Prognosis Of Leukemia Patients May Also Be A Therapeutic Target, Whitehead Institute and Children's Hospital Boston Reveals     7/12/2010
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down     3/1/2007
Researchers Develop New Strategy For The Treatment Of CML     1/18/2007
Role For Proteomics In Identifying Hematologic Malignancies     1/11/2007
Study Identifies Molecular Process Underlying Leukemia     8/22/2006
Cytoplasmic Location Of Shuttling Protein Often Seen With AML     1/20/2005
Perpetual AML Can Arise From Rare Leukemic Stem Cell     6/1/2004
Gene Expression Profiling Yields Prognostic Information For AML Patients     4/14/2004

Press Releases
Cornerstone Pharmaceuticals, Inc. Presents Phase I Data On CPI-613 In Acute Myeloid Leukemia (AML) And T-Cell Non-Hodgkin's Lymphoma (T-Cell NHL) At American Society of Hematology 2016     12/6/2016
Sunesis (SNSS) Announces Presentation Of Updated Results From The VALOR Trial Examining Overall Survival In Patients Age 60 Years And Older With Relapsed/Refractory AML At The American Society of Hematology Annual Meeting     12/6/2016
Actinium (ATNM.OB) Highlights Results From Phase I Clinical Trial Of Actimab-A At 58th American Society of Hematology Annual Meeting     12/6/2016
Agios (AGIO) Announces New Clinical Data From Dose-Escalation Portion Of Phase I Trial Of Single Agent AG-120 Showing Durable Molecular Responses In Patients With Advanced Hematologic Malignancies     12/6/2016
Helsinn And MEI Pharma (MEIP) Report Prolongation Of Survival Results From Phase 2 Clinical Study Of Pracinostat And Azacitidine In Acute Myeloid Leukemia     12/5/2016
Daiichi Sankyo Presents Phase 1 Data For MDM2 Inhibitor DS-3032 In Acute Myeloid Leukemia And Myelodysplastic Syndrome At The 58th Annual Meeting Of The American Society of Hematology     12/5/2016
GlycoMimetics, Inc. (GLYC)' GMI-1271 Continues To Yield High Remission Rates, Favorable Tolerability In Two Phase II Arms Of Ongoing Phase I/II Clinical Trial For AML     12/5/2016
Karyopharm (KPTI) Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting     12/5/2016
Seattle Genetics (SGEN) Highlights Phase I Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy With HMAs, In Patients With Acute Myeloid Leukemia At American Society of Hematology Annual Meeting     12/5/2016
Syros Pharma Presents Data At American Society of Hematology Annual Meeting Further Supporting Clinical Potential Of Its First-In-Class Selective Rara Agonist For Genomically Defined Subsets Of AML And MDS Patients     12/5/2016
BerGenBio AS Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML At American Society of Hematology 2016     12/2/2016
CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At European Organization for Research and Treatment of Cancer-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium     12/2/2016
Cyclacel Pharma (CYCC)’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential In Esophageal Cancer And Acute Leukemia     12/1/2016
ERYtech Pharma Presents New Data On GRASPA’s Mechanism Of Action At American Society of Hematology Annual Meeting     12/1/2016
Arog Pharmaceuticals Receives Orphan Drug Designation In The European Union For Crenolanib For The Treatment Of Acute Myeloid Leukemia And Soft Tissue Sarcoma     11/22/2016